ORR improvement in PD-L1+ (≥5% tumor cells) patients (prevalence: 35.4%): 52.7 vs. 10.8%; in PD-L1− patients: 33.1 vs. 15.7%. OS improvement: HR for death, 0.30 in PD-L1+ patients and 0.48 in PD-L1− patients. Here, CD274 is linked to neoplasm.